Medical Radiology and Radiation Safety. 2026. Vol. 71. № 5
DOI:10.33266/1024-6177-2026-71-5-20-32
G.G. Golyshev1, K.V. Tikunova1, Y. Deeni2, A.N. Goltsov1
ENHANCING TUMOUR RADIOSENSITIVITY BY TARGETING NRF2 ANTIOXIDANT SYSTEM
1 MIREA - Russian Technological University, Moscow, Russia
2 Federal University Dutse, Dutse, Nigeria
Contact person: Alexey Goltsov, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
ABSTRACT
The challenge of radioresistance in radiotherapy is currently tackled by introducing new radiotherapy facilities with high-quality of ionizing beams, high-precision of radiation delivery to tumour, and optimized treatment plans. This strategy is further enhanced by the development of new therapeutic methods for suppressing radioresistance in tumours of cancer patients by combining radiotherapy with chemo-, immuno-, and targeted therapies tailored to patients’ molecular profiles. As a result of numerous preclinical and clinical trials of the combination therapy, the primary molecular mechanisms, driving an increase in radiosensitivity, and the key cellular signalling pathways responsible for radioresistance were identified. One of the established radioresistance mechanisms involves adaptation of cancer cells to an elevated levels of reactive oxygen species (ROS) by activating antioxidant systems (AOS) of cellular protection and survival. Since radiotherapy mainly relies on ROS production that damages DNA, causing cancer cell death, activation of the AOS can mitigate radiotherapy effectiveness. Therefore, suppressing the AOS and its associated adaptation mechanisms may increase tumour radiosensitivity and enhance treatment outcomes.
In this review, we discuss the role of one of the key components of the cellular AOS which is under the control of the NRF2 transcription factor (nuclear erythroid factor 2) – a master regulator of cellular redox balance that protects cells from oxidative stress during radiotherapy by governing expression of a battery of antioxidant enzymes. We first outline the molecular mechanism of the redox-sensitive NRF2 AOS and its activation in response to the increased ROS levels following irradiation. We then evaluate experimental and clinical evidence regarding NRF2 activation in various cancer cells and tumours exposed to ionizing irradiation. Furthermore, we discuss results of numerous experimental and clinical investigations demonstrating that suppression of the NRF2 AOS enhances radiosensitivity of various cancers and improves radiotherapy outcomes. Collectively, these findings confirmed the potential of combining radiotherapy with targeted therapy aiming at the suppression of the NRF2 AOS. In this combination therapy NRF2 inhibitors act as radiosensitizers that promote overcoming radioresistance due to extra ROS accumulation and oxidative stress induction in cancer cells by inhibition of the NRF2-dependent antioxidant responses to radiotherapy.
Keywords: transcription factor NRF2, radiotherapy, radioresistance, radiosensitizer, antioxidant system, targeted therapy
For citation: Golyshev GG, Tikunova KV, Deeni Y, Goltsov AN. Enhancing Tumour Radiosensitivity by Targeting Nrf2 Antioxidant System. Medical Radiology and Radiation Safety. 2026;71(5):20–32. DOI:10.33266/1024-6177-2026-71-5-20-32
References
1. Meehan J, Gray M, Martínez-Pérez C, Kay C, Pang LY, Fraser JA, Poole AV, Kunkler IH, Langdon SP, Argyle D, Turnbull AK. Precision Medicine and the Role of Biomarkers of Radiotherapy Response in Breast Cancer. Front Oncol. 2020;10:628. doi:10.3389/fonc.2020.00628 PubMed PMID: 32391281; PubMed Central PMCID: PMC7193869.
2. Barker HE, Paget JTE, Khan AA, Harrington KJ. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer. 2015 Jul;15(7):409–25. doi:10.1038/nrc3958 PubMed PMID: 26105538; PubMed Central PMCID: PMC4896389.
3. Hayes JD, Dinkova-Kostova AT, Tew KD. Oxidative Stress in Cancer. Cancer Cell. 2020 Aug 10;38(2):167–97. doi:10.1016/j.ccell.2020.06.001.
4. Perillo B, Di Donato M, Pezone A, Di Zazzo E, Giovannelli P, Galasso G, Castoria G, Migliaccio A. ROS in cancer therapy: the bright side of the moon. Exp Mol Med. 2020 Feb;52(2):192–203. doi:10.1038/s12276-020-0384-2 PubMed PMID: 32060354; PubMed Central PMCID: PMC7062874.
5. Rojo de la Vega M, Chapman E, Zhang DD. NRF2 and the Hallmarks of Cancer. Cancer Cell. 2018 Jul 9;34(1):21–43. doi:10.1016/j.ccell.2018.03.022 PubMed PMID: 29731393; PubMed Central PMCID: PMC6039250.
6. Pizzino G, Irrera N, Cucinotta M, Pallio G, Mannino F, Arcoraci V, Squadrito F, Altavilla D, Bitto A. Oxidative Stress: Harms and Benefits for Human Health. Oxid Med Cell Longev. 2017;2017:8416763. doi:10.1155/2017/8416763 PubMed PMID: 28819546; PubMed Central PMCID: PMC5551541.
7. Oshi M, Gandhi S, Yan L, Tokumaru Y, Wu R, Yamada A, Matsuyama R, Endo I, Takabe K. Abundance of reactive oxygen species (ROS) is associated with tumor aggressiveness, immune response and worse survival in breast cancer. Breast cancer research and treatment. 2022 May 31;194(2):231. doi:10.1007/s10549-022-06633-0 PubMed PMID: 35639264.
8. Glorieux C, Liu S, Trachootham D, Huang P. Targeting ROS in cancer: rationale and strategies. Nat Rev Drug Discov. 2024 Aug;23(8):583–606. doi:10.1038/s41573-024-00979-4.
9. Baird L, Yamamoto M. The Molecular Mechanisms Regulating the KEAP1-NRF2 Pathway. Mol Cell Biol. 2020 Jun 15;40(13):e00099-20. doi:10.1128/MCB.00099-20 PubMed PMID: 32284348; PubMed Central PMCID: PMC7296212.
10. Taguchi K, Motohashi H, Yamamoto M. Molecular mechanisms of the Keap1–Nrf2 pathway in stress response and cancer evolution. Genes to Cells: Devoted to Molecular & Cellular Mechanisms. 2011 Feb;16(2):123–40. doi:10.1111/j.1365-2443.2010.01473.x PubMed PMID: 21251164.
11. Lau A, Villeneuve NF, Sun Z, Wong PK, Zhang DD. Dual roles of Nrf2 in cancer. Pharmacological research : the official journal of the Italian Pharmacological Society. 2008;58(5–6):262–70. doi:10.1016/j.phrs.2008.09.003 PubMed PMID: 18838122.
12. Kobayashi H, Imanaka S, Shigetomi H. Revisiting therapeutic strategies for ovarian cancer by focusing on redox homeostasis. Oncology letters. 2022 Mar 1;23:80. doi:10.3892/ol.2022.13200.
13. Kitamura H, Motohashi H. NRF2 addiction in cancer cells. Cancer Sci. 2018 Apr;109(4):900–11. doi:10.1111/cas.13537 PubMed PMID: 29450944; PubMed Central PMCID: PMC5891176.
14. Okazaki K, Papagiannakopoulos T, Motohashi H. Metabolic features of cancer cells in NRF2 addiction status. Biophys Rev. 2020 Feb 28;12(2):435–41. doi:10.1007/s12551-020-00659-8 PubMed PMID: 32112372; PubMed Central PMCID: PMC7242251.
15. Tufekci KU, Civi Bayin E, Genc S, Genc K. The Nrf2/ARE Pathway: A Promising Target to Counteract Mitochondrial Dysfunction in Parkinson’s Disease. Parkinsons Dis. 2011 Feb 22;2011:314082. Located at: C:Nrf2RefNRF2 Therapy. doi:10.4061/2011/314082 PubMed PMID: 21403858; PubMed Central PMCID: PMC3049335.
16. Mirzaei S, Zarrabi A, Hashemi F, Zabolian A, Saleki H, Azami N, Hamzehlou S, Farahani MV, Hushmandi K, Ashrafizadeh M, Khan H, Kumar AP. Nrf2 Signaling Pathway in Chemoprotection and Doxorubicin Resistance: Potential Application in Drug Discovery. Antioxidants (Basel). 2021 Feb 26;10(3):349. Located at: C:Nrf2RefNRF2 Therapy. doi:10.3390/antiox10030349 PubMed PMID: 33652780; PubMed Central PMCID: PMC7996755.
17. Boutten A, Goven D, Artaud-Macari E, Boczkowski J, Bonay M. NRF2 targeting: a promising therapeutic strategy in chronic obstructive pulmonary disease. Trends Mol Med. 2011 Jul;17(7):363–71. Located at: C:Nrf2RefNRF2 Therapy. doi:10.1016/j.molmed.2011.02.006 PubMed PMID: 21459041.
18. Dinkova-Kostova AT, Copple IM. Advances and challenges in therapeutic targeting of NRF2. Trends in Pharmacological Sciences. 2023 Mar 1;44(3):137–49. doi:10.1016/j.tips.2022.12.003 PubMed PMID: 36628798.
19. Li Y, Zhang X, Wang Z, Li B, Zhu H. Modulation of redox homeostasis: A strategy to overcome cancer drug resistance. Front Pharmacol. 2023 Mar 22;14. doi:10.3389/fphar.2023.1156538
20. Copple IM. The Keap1-Nrf2 cell defense pathway--a promising therapeutic target? Adv Pharmacol. 2012;63:43–79. doi:10.1016/B978-0-12-398339-8.00002-1 PubMed PMID: 22776639.
21. Lu MC, Ji JA, Jiang ZY, You QD. The Keap1-Nrf2-ARE Pathway As a Potential Preventive and Therapeutic Target: An Update. Med Res Rev. 2016 Sep;36(5):924–63. doi:10.1002/med.21396 PubMed PMID: 27192495.
22. Zhan X, Li J, Zhou T. Targeting Nrf2-Mediated Oxidative Stress Response Signaling Pathways as New Therapeutic Strategy for Pituitary Adenomas. Front Pharmacol. 2021 Mar 24;12. doi:10.3389/fphar.2021.565748.
23. Zhang J, Xu HX, Zhu JQ, Dou YX, Xian YF, Lin ZX. Natural Nrf2 Inhibitors: A Review of Their Potential for Cancer Treatment. Int J Biol Sci. 2023 Jun 4;19(10):3029–41. doi:10.7150/ijbs.82401 PubMed PMID: 37416770; PubMed Central PMCID: PMC10321279.
24. Zenkov NK, Menshchikova EB, Tkachev VO. Keap1/Nrf2/ARE redox-sensitive signaling system as a pharmacological target diseases. Biochemistry (Moscow). 2013;78(1):27–47.
25. Marampon F, Codenotti S, Megiorni F, Del Fattore A, Camero S, Gravina GL, Festuccia C, Musio D, De Felice F, Nardone V, Santoro AN, Dominici C, Fanzani A, Pirtoli L, Fioravanti A, Tombolini V, Cheleschi S, Tini P. NRF2 orchestrates the redox regulation induced by radiation therapy, sustaining embryonal and alveolar rhabdomyosarcoma cells radioresistance. Journal of Cancer Research and Clinical Oncology. 2019 Apr;145(4):881–93. doi:10.1007/s00432-019-02851-0.
26. Golyshev GG, Tikunova KV, Zaytsev OA, Deene Y, Goltsov AN. NRF2 antioxidant cellular system as a therapeutic target for enhancing cancer radiosensitivity. Medical Physics. 2025;(1):94–109. doi:10.52775/1810-200X-2025-105-1-94-109.
27. McMahon M, Thomas N, Itoh K, Yamamoto M, Hayes JD. Dimerization of Substrate Adaptors Can Facilitate Cullin-mediated Ubiquitylation of Proteins by a “Tethering” Mechanism:
A TWO-SITE INTERACTION MODEL FOR THE Nrf2-Keap1 COMPLEX*. Journal of Biological Chemistry. 2006 Aug 25;281(34):24756–68. doi:10.1074/jbc.M601119200.
28. Suzuki T, Yamamoto M. Molecular basis of the Keap1-Nrf2 system. Free Radic Biol Med. 2015 Nov;88(Pt B):93–100. doi:10.1016/j.freeradbiomed.2015.06.006 PubMed PMID: 26117331.
29. Hayes JD, Dinkova-Kostova AT. The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. Trends in Biochemical Sciences. 2014 Apr;39(4):199–218. doi:10.1016/j.tibs.2014.02.002 PubMed PMID: 24647116.
30. Apopa PL, He X, Ma Q. Phosphorylation of Nrf2 in the transcription activation domain by casein kinase 2 (CK2) is critical for the nuclear translocation and transcription activation function of Nrf2 in IMR-32 neuroblastoma cells. J Biochem Mol Toxicol. 2008 Feb;22(1):63–76. doi:10.1002/jbt.20212 PubMed PMID: 18273910.
31. Liu T, Lv YF, Zhao JL, You QD, Jiang ZY. Regulation of Nrf2 by phosphorylation: Consequences for biological function and therapeutic implications. Free Radical Biology and Medicine. 2021 May 20;168:129–41. doi:10.1016/j.freeradbiomed.2021.03.034.
32. Kaspar JW, Jaiswal AK. Tyrosine phosphorylation controls nuclear export of Fyn, allowing Nrf2 activation of cytoprotective gene expression. FASEB J. 2011 Mar;25(3):1076–87. doi:10.1096/fj.10-171553 PubMed PMID: 21097520; PubMed Central PMCID: PMC3042843.
33. Zhang Q, Pi J, Woods CG, Andersen ME. A systems biology perspective on Nrf2-mediated antioxidant response. Toxicol Appl Pharmacol. 2010 Apr 1;244(1):84–97. doi:10.1016/j.taap.2009.08.018 PubMed PMID: 19716833; PubMed Central PMCID: PMC2837757.
34. Liu S, Pi J, Zhang Q. Signal amplification in the KEAP1-NRF2-ARE antioxidant response pathway. Redox Biol. 2022 Aug;54:102389. doi:10.1016/j.redox.2022.102389 PubMed PMID: 35792437; PubMed Central PMCID: PMC9287733.
35. Khalil HS, Goltsov A, Langdon SP, Harrison DJ, Bown J, Deeni Y. Quantitative analysis of NRF2 pathway reveals key elements of the regulatory circuits underlying antioxidant response and proliferation of ovarian cancer cells. Journal of Biotechnology. 2015 May;202:12–30. doi:10.1016/J.JBIOTEC.2014.09.027 PubMed PMID: 25449014.
36. Kawasaki Y, Okumura H, Uchikado Y, Kita Y, Sasaki K, Owaki T, Ishigami S, Natsugoe S. Nrf2 is Useful for Predicting the Effect of Chemoradiation Therapy on Esophageal Squamous Cell Carcinoma. Annals of Surgical Oncology. 2014 Jul 1;21(7):2347–52. doi:10.1245/s10434-014-3600-2.
37. Singh A, Bodas M, Wakabayashi N, Bunz F, Biswal S. Gain of Nrf2 Function in Non-Small-Cell Lung Cancer Cells Confers Radioresistance. Antioxidants & Redox Signaling. 2010 Dec;13(11):1627–37. doi:10.1089/ars.2010.3219.
38. Tang T, Jia Y, Liang H, Han Y, Cong Z, Wang H, Ji X. Knockdown of Nrf2 radiosensitizes glioma cells by inducing redox stress and apoptosis in hypoxia. Transl Cancer Res. 2022 Nov;11(11):4105–16. doi:10.21037/tcr-22-1420 PubMed PMID: 36523295; PubMed Central PMCID: PMC9745379.
39. McMahon SJ. The linear quadratic model: usage, interpretation and challenges. Phys Med Biol. 2018 Dec 19;64(1):01TR01. doi:10.1088/1361-6560/aaf26a PubMed PMID: 30523903.
40. Xia D, Zhang XR, Ma YL, Zhao ZJ, Zhao R, Wang YY. Nrf2 promotes esophageal squamous cell carcinoma (ESCC) resistance to radiotherapy through the CaMKIIα-associated activation of autophagy. Cell & Bioscience. 2020 Jul 30;10(1):90. doi:10.1186/s13578-020-00456-6.
41. McDonald JT, Kim K, Norris AJ, Vlashi E, Phillips TM, Lagadec C, Della Donna L, Ratikan J, Szelag H, Hlatky L, McBride WH. Ionizing radiation activates the Nrf2 antioxidant response. Cancer Res. 2010 Nov 1;70(21):8886–95. doi:10.1158/0008-5472.CAN-10-0171 PubMed PMID: 20940400; PubMed Central PMCID: PMC2970706.
42. Jayakumar S, Kunwar A, Sandur SK, Pandey BN, Chaubey RC. Differential response of DU145 and PC3 prostate cancer cells to ionizing radiation: role of reactive oxygen species, GSH and Nrf2 in radiosensitivity. Biochim Biophys Acta. 2014 Jan;1840(1):485–94. doi:10.1016/j.bbagen.2013.10.006 PubMed PMID: 24121106.
43. Matsuoka Y, Yoshida R, Kawahara K, Sakata J, Arita H, Nkashima H, Takahashi N, Hirayama M, Nagata M, Hirosue A, Kuwahara Y, Fukumoto M, Toya R, Murakami R, Nakayama H. The antioxidative stress regulator Nrf2 potentiates radioresistance of oral squamous cell carcinoma accompanied with metabolic modulation. Laboratory Investigation. 2022 Aug 1;102(8):896–907. doi:10.1038/s41374-022-00776-w PubMed PMID: 35414650.
44. Feng L, Zhao K, Sun L, Yin X, Zhang J, Liu C, Li B. SLC7A11 regulated by NRF2 modulates esophageal squamous cell carcinoma radiosensitivity by inhibiting ferroptosis. Journal of Translational Medicine. 2021 Aug 26;19(1):367. doi:10.1186/s12967-021-03042-7.
45. Wannouss M, Golyshev GG, Goltsov AN. Classification of cancer cell lines on their radiosensitivity by machine learning. Annals of Biostatistics & Biometric Applications. 2023;5(2):2–5.
46. Wannouss M, Shemel VD, Golyshev GG, Goltsov AN. Method for determining radioresistance of cancer cell lines based on cluster analysis of clonogenic cell survival data. Medical Physics (Moscow). 2024;(1):18–35.
47. Lee S, Lim MJ, Kim MH, Yu CH, Yun YS, Ahn J, Song JY. An effective strategy for increasing the radiosensitivity of Human lung Cancer cells by blocking Nrf2-dependent antioxidant responses. Free Radic Biol Med. 2012 Aug 15;53(4):807–16. doi:10.1016/j.freeradbiomed.2012.05.038 PubMed PMID: 22684019.
48. Xue M, Momiji H, Rabbani N, Barker G, Bretschneider T, Shmygol A, Rand DA, Thornalley PJ. Frequency Modulated Translocational Oscillations of Nrf2 Mediate the Antioxidant Response Element Cytoprotective Transcriptional Response. Antioxid Redox Signal. 2015 Sep 1;23(7):613–29. doi:10.1089/ars.2014.5962 PubMed PMID: 25178584; PubMed Central PMCID: PMC4556091.
49. Trachootham D, Lu W, Ogasawara MA, Nilsa RDV, Huang P. Redox regulation of cell survival. Antioxid Redox Signal. 2008 Aug;10(8):1343–74. doi:10.1089/ars.2007.1957 PubMed PMID: 18522489; PubMed Central PMCID: PMC2932530.
50. Ribeiro B. Glutathione: the master antioxidant. Ozone therapy global journal. 2023;13(1):175–97.
51. Sideri S, Petragnano F, Maggio R, Petrungaro S, Catizone A, Gesualdi L, De Martino V, Battafarano G, Del Fattore A, Liguoro D, De Cesaris P, Filippini A, Marampon F, Riccioli A. Radioresistance Mechanisms in Prostate Cancer Cell Lines Surviving Ultra-Hypo-Fractionated EBRT: Implications and Possible Clinical Applications. Cancers (Basel). 2022 Nov 9;14(22):5504. doi:10.3390/cancers14225504 PubMed PMID: 36428597; PubMed Central PMCID: PMC9688510.
52. Jeong Y, Hoang NT, Lovejoy A, Stehr H, Newman AM, Gentles AJ, Kong W, Truong D, Martin S, Chaudhuri A, Heiser D, Zhou L, Say C, Carter JN, Hiniker SM, Loo BW, West RB, Beachy P, Alizadeh AA, Diehn M. Role of KEAP1/NRF2 and TP53 Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance. Cancer Discov. 2017 Jan;7(1):86–101. doi:10.1158/2159-8290.CD-16-0127 PubMed PMID: 27663899; PubMed Central PMCID: PMC5222718.
53. Fabrizio FP, Sparaneo A, Trombetta D, Muscarella LA. Epigenetic versus Genetic Deregulation of the KEAP1/NRF2 Axis in Solid Tumors: Focus on Methylation and Noncoding RNAs. Oxid Med Cell Longev. 2018;2018:2492063. doi:10.1155/2018/2492063 PubMed PMID: 29643973; PubMed Central PMCID: PMC5872633.
54. Sparaneo A, Torrisi F, D’Angeli F, Giurdanella G, Bravaccini S, Muscarella LA, Fabrizio FP. Decoding the NRF2–NOTCH Crosstalk in Lung Cancer—An Update. Antioxidants (Basel). 2025 May 29;14(6):657. doi:10.3390/antiox14060657 PubMed PMID: 40563292; PubMed Central PMCID: PMC12190023.
55. Singh A, Misra V, Thimmulappa RK, Lee H, Ames S, Hoque MO, Herman JG, Baylin SB, Sidransky D, Gabrielson E, Brock MV, Biswal S. Dysfunctional KEAP1–NRF2 Interaction in Non-Small-Cell Lung Cancer. PLOS Medicine. 2006 Oct 3;3(10):e420. doi:10.1371/journal.pmed.0030420.
56. Konstantinopoulos PA, Spentzos D, Fountzilas E, Francoeur N, Sanisetty S, Grammatikos AP, Hecht JL, Cannistra SA. Keap1 Mutations and Nrf2 Pathway Activation in Epithelial Ovarian Cancer. Cancer Research. 2011 Jul 28;71(15):5081–9. doi:10.1158/0008-5472.CAN-10-4668.
57. Zhang P, Singh A, Yegnasubramanian S, Esopi D, Kombairaju P, Bodas M, Wu H, Bova GS, Biswal S. Molecular cancer therapeutics. 2010 Feb 2;9(2):336. doi:10.1158/1535-7163.MCT-09-0589 PubMed PMID: 20124447.
58. Yoo NJ, Kim HR, Kim YR, An CH, Lee SH. Somatic mutations of the KEAP1 gene in common solid cancers. Histopathology. 2012 May;60(6):943–52. doi:10.1111/j.1365-2559.2012.04178.x PubMed PMID: 22348534.
59. Ooi A, Dykema K, Ansari A, Petillo D, Snider J, Kahnoski R, Anema J, Craig D, Carpten J, Teh BT, Furge KA. CUL3 and NRF2 mutations confer an NRF2 activation phenotype in a sporadic form of papillary renal cell carcinoma. Cancer Research. 2013 Apr;73(7):2044–51. doi:10.1158/0008-5472.CAN-12-3227 PubMed PMID: 23365135.
60. Jiang T, Chen N, Zhao F, Wang XJ, Kong B, Zheng W, Zhang DD. High Levels of Nrf2 Determine Chemoresistance in Type II Endometrial Cancer. Cancer Research. 2010 Jun 30;70(13):5486–96. doi:10.1158/0008-5472.CAN-10-0713.
61. DeBlasi JM, Falzone A, Caldwell S, Prieto-Farigua N, Prigge JR, Schmidt EE, Chio IIC, Karreth FA, DeNicola GM. Distinct Nrf2 Signaling Thresholds Mediate Lung Tumor Initiation and Progression. Cancer Res. 2023 Jun 15;83(12):1953–67. doi:10.1158/0008-5472.CAN-22-3848 PubMed PMID: 37062029; PubMed Central PMCID: PMC10267679.
62. Khalil HS, Langdon SP, Goltsov A, Soininen T, Harrison DJ, Bown J, Deeni YY. A novel mechanism of action of HER2 targeted immunotherapy is explained by inhibition of NRF2 function in ovarian cancer cells. Oncotarget. 2016 Oct. doi:10.18632/oncotarget.12425.
63. Tao S, Wang S, Moghaddam SJ, Ooi A, Chapman E, Wong PK, Zhang DD. Oncogenic KRAS confers chemoresistance by upregulating NRF2. Cancer Research. 2014 Dec;74(24):7430–41. doi:10.1158/0008-5472.CAN-14-1439 PubMed PMID: 25339352; PubMed Central PMCID: PMC4268230.
64. Chen W, Sun Z, Wang XJ, Jiang T, Huang Z, Fang D, Zhang DD. Direct Interaction between Nrf2 and p21Cip1/WAF1 Upregulates the Nrf2-Mediated Antioxidant Response. Molecular Cell. 2009 Jun 26;34(6):663–73. doi:10.1016/j.molcel.2009.04.029 PubMed PMID: 19560419.
65. Copple IM. The Keap1-Nrf2 cell defense pathway–a promising therapeutic target? Advances in Pharmacology (San Diego, Calif). 2012;63:43–79. doi:10.1016/B978-0-12-398339-8.00002-1 PubMed PMID: 22776639.
66. Barbano R, Muscarella LA, Pasculli B, Valori VM, Fontana A, Coco M, la Torre A, Balsamo T, Poeta ML, Marangi GF, Maiello E, Castelvetere M, Pellegrini F, Murgo R, Fazio VM, Parrella P. Aberrant Keap1 methylation in breast cancer and association with clinicopathological features. Epigenetics. 2013 Jan 1;8(1):105–12. doi:10.4161/epi.23319 PubMed PMID: 23249627; PubMed Central PMCID: PMC3549873.
67. Muscarella LA, Barbano R, D’Angelo V, Copetti M, Coco M, Balsamo T, la Torre A, Notarangelo A, Troiano M, Parisi S, Icolaro N, Catapano D, Valori VM, Pellegrini F, Merla G, Carella M, Fazio VM, Parrella P. Regulation of KEAP1 expression by promoter methylation in malignant gliomas and association with patient’s outcome. Epigenetics. 2011 Mar;6(3):317–25. doi:10.4161/epi.6.3.14408 PubMed PMID: 21173573; PubMed Central PMCID: PMC3092680.
68. Darnell JE. Transcription factors as targets for cancer therapy. Nat Rev Cancer. 2002 Oct;2(10):740–9. doi:10.1038/nrc906
69. Bushweller JH. Targeting transcription factors in cancer ‒ from undruggable to reality. Nat Rev Cancer. 2019 Nov;19(11):611–24. doi:10.1038/s41568-019-0196-7 PubMed PMID: 31511663; PubMed Central PMCID: PMC8820243.
70. Galeaz C, Totis C, Bisio A. Radiation Resistance: A Matter of Transcription Factors. Front Oncol. 2021;11:662840. doi:10.3389/fonc.2021.662840 PubMed PMID: 34141616; PubMed Central PMCID: PMC8204019.
71. Zhou S, Ye W, Shao Q, Zhang M, Liang J. Nrf2 is a potential therapeutic target in radioresistance in human cancer. Critical Reviews in Oncology/Hematology. 2013 Dec;88(3):706–15. doi:10.1016/j.critrevonc.2013.09.001 PubMed PMID: 24126138.
72. Paramasivan P, Kankia IH, Langdon SP, Deeni YY. Emerging role of nuclear factor erythroid 2-related factor 2 in the mechanism of action and resistance to anticancer therapies. Cancer Drug Resistance. 2019 Sep 19;2(3):490–515. doi:10.20517/cdr.2019.57.
73. Goloborodko EV, Kretov AS, Makarov DYu. Non-Drug Methods of Increasing the Radioresistance (Literature Review). MEDICAL RADIOLOGY AND RADIATION SAFETY. 2026;71(3):30–3. doi:10.33266/1024-6177-2026-71-3-30-33.
74. Telkoparan-Akillilar P, Panieri E, Cevik D, Suzen S, Saso L. Therapeutic Targeting of the NRF2 Signaling Pathway in Cancer. Molecules. 2021 Mar 5;26(5):1417. doi:10.3390/molecules26051417 PubMed PMID: 33808001; PubMed Central PMCID: PMC7961421.
75. Pouremamali F, Pouremamali A, Dadashpour M, Soozangar N, Jeddi F. An update of Nrf2 activators and inhibitors in cancer prevention/promotion. Cell Communication and Signaling. 2022 Dec;20(1):100. doi:10.1186/s12964-022-00906-3.
76. El-Naggar AM, Somasekharan SP, Wang Y, Cheng H, Negri GL, Pan M, Wang XQ, Delaidelli A, Rafn B, Cran J, Zhang F, Zhang H, Colborne S, Gleave M, Mandinova A, Kedersha N, Hughes CS, Surdez D, Delattre O, Wang Y, Huntsman DG, Morin GB, Sorensen PH. Class I HDAC inhibitors enhance YB-1 acetylation and oxidative stress to block sarcoma metastasis. EMBO Rep. 2019 Dec 5;20(12):e48375. doi:10.15252/embr.201948375 PubMed PMID: 31668005; PubMed Central PMCID: PMC6893361.
PDF (RUS) Full-text article (in Russian)
Conflict of interest.The authors declare no conflict of interest.
Financing. This work was supported by the Ministry of Science and Higher Education of the Russian Federation (grant No. FGFZ-2026-0007).
Contribution. Article was prepared with equal participation of the authors.
Article received: 20.04.2026. Accepted for publication: 25.05.2026.